Updating results

4 results for TA393

Sort: Relevance | Date

Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA393)

Evidence-based recommendations on alirocumab (Praluent) for treating primary hypercholesterolaemia (high cholesterol) and mixed dyslipidaemia

Technology appraisal guidance Published June 2016

Familial hypercholesterolaemia

Everything NICE has said on familial hypercholesterolaemia in an interactive flowchart

NICE Pathway Published August 2013 Last updated October 2019

NICE impact: cardiovascular disease prevention

How NICE recommendations are helping to improve the prevention of cardiovascular disease

Published May 2018 Last updated May 2018